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We have investigated the propensity to form fibrillar aggregates of a variety of fragments and variants of the tau protein under the influence
of a tau fibrillization inducer: coenzyme Q0. To better identify fibrillization hotspots, we compare the polymerization propensity of tau
fragments containing the sequence of putative hotspots with that of tau variants with that same sequence deleted. We also investigate the effects
of biologically occurring modifications such as phosphorylation and deamidation. We found that residues 305 to 335 are essential for in vitro
tau fibrillization. Residues 306 to 311 facilitate in vitro assembly, but are not sufficient to mimic the in vivo fibrillization of tau. Furthermore,
the propensity of the 306–311 sequence to form fibrils is highly decreased by chemical modifications of tyrosine 310 that are commonly found
in vivo.
© 2006 Elsevier B.V. All rights reserved.Keywords: Tau; Polymerization; Coenzyme Q0; Tau variant1. Introduction
Alzheimer's disease is characterized by the appearance of
two aberrant structures in the brain of patients: senile plaques
(SP) and neurofibrillary tangles (NFTs) [1]. NFTs are
intracellular inclusions made of clumps of protein fibers
termed paired helical filaments (PHFs) [2]. About 20 years
ago it was found that the microtubule associated protein tau is
a major component of PHFs [3–9] and that purified tau was
able to assemble in vitro into fibrillar polymers that resemble
the morphology of ex vivo PHFs (from here on we use the
term PHF exclusively to denote in vivo produced material)
[10]. Subsequent studies revealed that PHFs were rich in a
phosphorylated protein [11], which turned out to be a hyper-
phosphorylated form of tau [12,13]. Aberrant phosphotau
polymers also appear associated with other neurological
diseases like Pick's disease, frontotemporal dementia linked⁎ Corresponding author. Tel.: +34 91 497 8460; fax: +34 914974799.
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doi:10.1016/j.bbadis.2006.06.003to chromosome 17, corticobasal degeneration, and progres-
sive supranuclear palsy [14]. Interestingly, all these disorders
are characterized by the presence of dementia symptoms
[15].
Intriguingly, and in contrast to the β-amyloid peptides [16],
tau protein has very low propensity to aggregate. This property
has made difficult the development of in vitro procedures that
faithfully mimic PHF formation. For instance, the hanging drop
assay, as used for protein crystallization, renders tau fibrils with
PHF-like ultra-structure, but requires extremely high protein
concentrations [17]. Such limitation is often overcome by
enzymatically modifying tau, or with the addition of com-
pounds that facilitate tau assembly (i.e., inducers). Protein
phosphorylation [18], glycation [19,20], deamination [10,21]
and truncation by protein cleavage [22], have all been reported
to increase the propensity of tau to fibrillize in vitro. Some
examples of molecules that act as inducers are sulfated
glycosaminoglycans (e.g., heparin [23,24]), other polyanions
[25], fatty acids such as arachidonic acid [26,27], or products
resulting from the oxidation of arachidonic acid like hydro-
xinonenal (HNE) [28]. More recently, Coenzyme Q0 and other
Fig. 1. Assembly of tau in the presence of quinones. Tau protein (1 mg/ml) was
mixed with Coenzyme Q0 (1 mM) and the assembled polymers from tau were
visualized by electron microscopy (A). The length distribution of the polymers
is shown in panel B.
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fibrillization [29]. In all these cases the concentration of tau
required for its assembly is dramatically decreased (for a review
see [30]).
Tau is also a large protein (i.e., 441 residues for the human
full-length tau) with 6 different isoforms produced by alter-
native splicing [31,32], thus suggesting that only a fraction of
the molecule should be involved in its fibrillization. Indeed,
analysis of the PHF core showed that only a fragment of ∼100
residues from the tubulin binding domain of tau is involved in
forming the PHF scaffold [33]. The tubulin binding domain of
tau comprises three (tau 3R) or four (tau 4R) repeated regions
with similar aminoacid sequences [34,35]. It has later been
proposed that it is the third repeat region of the tubulin binding
domain the one primarily involved in tau fibrillization, with the
second repeat playing a surrogate role in the assembly reaction
[24]. Following these ideas, in this work we investigate the in
vitro fibrillization of tau using Coenzyme Q0, as inducer for
polymerization of different tau fragments and/or variants with
the goal of identifying the regions of tau that participate in PHF
formation.
2. Materials and methods
2.1. Materials
2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q0, ref no. D-9150),
p-Benzoquinone (Ref. B-1266) was obtained from Aldrich (Steinheim,
Germany). Acrylamide/bisacrylamide solution was supplied by Bio-Rad.
Synthetic oligonucleotides were purchased from Isogen (Belgium) and peptides
were obtained from NeoMPS (Strasbourg, France).
2.2. Construction of expression plasmids of three different tau deletion
mutants
The plasmid pRKT42 [24], which encodes a human 4-repeat tau isoform with
twoN-terminal exons, was used a template. To obtain other constructs,mutagenesis
was carried out in the parent plasmid pRKT42 using the polymerase chain reaction







CAGGTCAACTGGTTTGTA) were used as 3′ primers.
Oligonucleotide A6 (CGGGATCCATAATGGCTGAGCCC), which
includes the initiation codon as well as BamHI and NdeI sites for a proper
cloning onto the vector, was used as 5′ primer. The obtained fragment was
used as template for a second PCR. Oligonucleotide A8 (GCGAATTCT-
CACAAACCCTGCTTGG), which includes a stop codon as well an EcoRI
site downstream, was used as the 3′ primer. The fragments generated by
PCR amplification were digested with NdeI and EcoRI and the ligated into
NdeI–EcoRI-digested pRK172. A similar approach was done to isolate tau
deletion mutants using the plasmid pRKT30, which encodes a human three-
repeat tau isoform.
2.3. Protein and peptide preparation
Recombinant human tau (whole molecule), tau fragment 1 (containing the
amino-terminal half of tau protein), tau fragment 2 (containing the four tubulin
binding motifs and the carboxyl-terminal region), tau fragment 3 (containing the
four tubulin binding motifs), tau fragment 4 (containing the second and thirdtubulin binding motifs), and tau fragment 5 (containing the carboxy-terminal
region), were isolated as previously described, [29] (see Fig. 7 for a scheme of
the tau fragments used here). Among, tau variants we have used tau protein with
the four tubulin binding repeats (tau 4R) but lacking residues 306–311 (tau
4RΔ306−311), or tau protein with three tubulin binding repeats (tau 3R), lacking
the equivalent residues (first six residues located at the 3rd repeat) of tau 4R
(tau3RΔ275−281). Also, we have used those tau proteins lacking the whole 3
rd
repeat (tau 4RΔ305–335) or residues 321–335 (tau 4RΔ321–335). In this work,
also we use the following peptides, which have been synthesized with solid-
phase methods and purified as previously reported [36]. Peptide I (first repeat):
QTAPVPMPDLKNVKSKIGSTENLKHQPGGGK; peptide II (second repeat):
VQIINKKLDLSNVQSKCGSKDNIKHVPGGGS; peptide IIa: VQIINK; pep-
tide IIb: NVQSKCGSKDNIKHVPGGGS; peptide III (third repeat): VQI-
VYKPVDLSKVTSKCGSLGNIHHKPGGGQ; peptide IIIa: VQIVYK (also
tested with tyrosine in phosphorylated form, or replaced by phenylalanine);
peptide IIIi: PVDLSKVTS; peptide IIIb: KCGSLGNIHHKPGGGQ and peptide
IV (four repeat): VEVKSEKLDFKDRVQSKIGSLDNITHVPGGGN.
2.4. Assembly of Tau peptides into filaments
Filaments were grown by vapor diffusion in hanging drops, as previously
described [24]. For assembly of peptides in the presence of quinones, tau protein
(0.5–2 mg/ml) in final volume between 20 μl and 1 ml, was incubated at 4 °C, in
a buffer containing 0.1 MMES pH 6.4, 0.5 mMMgCl2, 2 mM EGTA (buffer A)
plus 50 mM NaCl, in the absence, or the presence, of 0.25 mM to 4 mM of
685I. Santa-María et al. / Biochimica et Biophysica Acta 1762 (2006) 683–692coenzyme Q0. The reservoir for the hanging drop assay [37] contained 0.2 M
NaCl in buffer A.
2.5. Measurements of aggregated or polymerized protein
To quantify the amount of polymerized protein, samples were centrifuged
for 30 min at maximum speed in an Airfuge (Beckman). The protein present in
supernatant and pellet was analyzed by gel electrophoresis followed by western
blot using tau antibody 7.51 (a kind gift of Dr. C. Wischik, UK). The amount of
protein was quantified by densitometry.
2.6. Electron microscopy
The samples were prepared and visualized under the transmission electron
microscope as previously indicated [24].
2.7. Immunofluorescence studies
Tau fibrillar polymers were visualized by immunofluorescence, using a
variation of the technique employed for microtubule visualization [38,39], by
a novel technique [40]. Briefly, a suspension of tau polymers was placed in a
corex tube containing a glass coverslip. After centrifugation at 1500 rpm in a
HB4 rotor for 60 min at room temperature, the protein sedimented on the
coverslip was fixed with 4% paraformaldehyde, and processed for double
immunofluorescence [38] using an antibody raised against tau (T14)(1:500)
and 0.01% thioflavin S. With this technique, tau filaments, that cannot be
seen under the optic microscopy, can be visualized under a fluorescent
microscope. Fluorescence microscopy was used to measure fluorescence
intensity. Fibrillar polymers were observed with a Zeiss Axiovert200
fluorescent microscope. T14 antibody (obtained from Zymed, CA, USA)
and thioflavin-S fluorescence images were captured through a 100× objectiveFig. 2. Assembly of the different peptides comprising the 3rd tubulin binding repea
tubulin binding repeat, divided in three peptides, IIIa, IIIi, IIIb, is shown. (B) Assem
Assembly of the three peptides in the presence of Coenzyme Q0 (see Materials andon a high-resolution CCD camera (SPOT RT Slider, Diagnostic). The images
were saved for later analysis and quantification. Camera exposure and light
settings were kept constant during each experiment.
The fluorescence intensity measurements were carried out using the image
analysis software Metamorph 6.1 r6 (Universal Imaging).
2.8. Iodination of tau peptide IIIa
The peptide was labeled with iodine using the chloramine T technique. The
peptide was further purified by gel filtration as described previously
(Antibodies. A laboratory manual. Chapter 9. by Ed. Harlow and D Lane.
Cold Spring Harbor Laboratory).3. Results and discussion
3.1. Tau fibrillization induced by quinones
As we have described previously [29], tau readily fibrillizes
in vitro in the presence of quinones (see Fig. 1A). The length
distribution of these polymers is shown in Fig. 1B. An average
length of 0.23 μm was found. This average length was different
to that described for heparin-promoted tau polymers (around
0.8 μm), using similar assembly conditions to those used in the
presence of quinones [24]. Also, assembly of longer polymers
was found in the presence of heparin but using a different
assembly buffer [37]. In that case also very tiny filaments
(“dashed minifilaments”) were observed together with the long
filaments. About the diameter of the filaments, a range fromt, in the presence of quinones. (A) A scheme of tau molecule showing the 3rd
bly of the three peptides (1 mg/ml) in the absence of any added compound. (C)
methods).
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[24,37], and range from 10 nm to 15 nm was observed for
quinone-induced filaments.
3.2. The role of the tubulin binding repeats II and III in tau
assembly
Several reports have shown that peptides corresponding to
the isolated sequences of repeats II or III can fibrillize in vitro
[17,24,41,42]. Here, we perform a complementary experiment.
The experiment consists in investigating the fibrillization
ability of a variant of tau with repeats II and III deleted. If
repeats II and III are, indeed, the hotspots for fibrillization of
full-length tau, a variant with both repeats deleted should prove
unable to fibrillize in vitro. To thoroughly test this idea, weFig. 3. Assembly of tau protein variants lacking some residues from the 3rd tubuli
experiment. (B) The whole tau protein (●) or variants lacking the whole third tubulin
IIIb (317–335) (▪), or lacking the residues comprising peptide IIIa (306–311) (▴)
amount of assembled polymers was measured after their centrifugation (see Materia
lacks segments IIIa, or IIIb and it is not found in the absence of the whole repeat. Pane
and tau lacking peptide IIIb, respectively.attempted to fibrillize this tau variant with quinones. Quinones
failed to induce fibrillization of the tau variant without repeats
II and III even at relatively high concentrations (i.e., 2 μg/μl)
(data not shown). These results indicate that, in addition to
being able to fibrillize independently, repeats II and III
comprise the sequence critical for inducing tau fibrillization
in vitro. Interestingly, a tau isoform that naturally lacks repeat
II is able to fibrillize in vitro [17], thus suggesting that the
fibrillization hotspot can be mapped more precisely as part of
repeat III. To analyze this region of the whole tau (tau 4R) we
divided it in three short segments: peptide IIIa (residues 306 to
311), peptide IIIi (residues 312 to 320) and peptide IIIb
(residues 321 to 335) (see Fig. 2A). Peptides encompassing
each of these three sequences were able to fibrillize in the
presence of quinones (Fig. 2C). However, peptide IIIin binding region. (A) Scheme of tau 4R protein and its variants tested in this
binding repeat (residues 305–335) (♦), lacking the residues comprising peptide
were mixed at a concentration of 1 mg/ml with Coenzyme Q0 (2 mM), and the
ls and methods). Panel B shows a decrease in protein polymerization when tau
ls C–E show examples of the fibrils assembled from tau, tau lacking peptide IIIa
Fig. 4. Thioflavin-S fluorescence of tau and tau (lacking peptide IIIa) polymers. (A) The whole tau containing the four tubulin binding repeats (tau 4R) and tau 4R
variant lacking peptide IIIa (residues 306–311 in tau 4R)(tau 4RΔ306–311) were assembled and visualized by immunofluorescence (see Materials and methods) using
tau antibody T14 and/or thioflavin-S. The obtained results and the merge of T14 plus thioflavin-S images are shown. (B) As in (A) but testing tau 3R and tau 3R variant
lacking the equivalent peptide IIIa (residues 275–281)(tau 3RΔ275–281) from tau 4R. (C) Quantification of the thioflavin fluorescence observed by fluorescence
microscopy. The fluorescence intensity of the filament area was obtained by background subtraction. Tau variants lacking peptide IIIa show a significantly reduced
fluorescence intensity (n=10, P<0.01 as compared with tau 4R or with tau 3R).
687I. Santa-María et al. / Biochimica et Biophysica Acta 1762 (2006) 683–692
688 I. Santa-María et al. / Biochimica et Biophysica Acta 1762 (2006) 683–692fibrillized with significantly lower efficiency than the other
two. Peptide IIIa, which is only 6 residues long, fibrillizes
readily even in the absence of any added inducer (Fig. 2B).
The high intrinsic tendency to fibrillize of peptide IIIa could
indicate that this short sequence contains the fibrillization
hotspot for tau. At this level of dissection (from over 400
residues down to 6) it is important to exert caution, however,
because short unstructured peptides have high intrinsic
propensity to aggregate into β-amyloid fibrils [43]. Indeed, a
tau variant lacking this segment of six residues displays a
reduced propensity to fibrillize in the presence of quinones, butFig. 5. Assembly of peptide VQIINK and its variants. Assembly of the second tubulin
in tau molecule is shown. Also, the variant of that peptide where aspartic acid replaces
absence of any added compound. (Ab) No fibrils were observed for VQIIDK. (B) Sch
was mutated to aspartic acid. (Ba) Assembly of the second repeat peptide in the pr
presence of quinone.fibrillar polymers can still be found. Fig. 3A shows the polymers
from tau 4R and Fig. 3B, those assembled from tau variant
lacking those six residues (tau 4RΔ306−311). Additionally, Fig.
3C and D shows two examples of those polymers assembled
from tau variant lacking residues 317–335 (tau 4RΔ317–335).
The few fibrils observed are comprised of tau molecules, as
observed by immunofluorescence with tau antibody T14 (Fig.
4A), and display decreased thioflavin-S fluorescence (Fig. 4A,
and C for the quantitative analysis). This result was found by
testing both tau 4R (Fig. 4A) or tau 3R (Fig. 4B) variants lacking
that segment of six residues.binding repeat peptide. (A) A scheme of the localization of tau peptide VQIINK
asparagine is indicated. (Aa) Few fibrils from VQIINK peptide were found in the
eme of the second tubulin binding repeat peptide and its variant whose asparagine
esence of quinone. (Bb) Assembly of the mutated second repeat peptide in the
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Tau protein extracted from Alzheimer's disease patients
often has the asparagine of peptide IIa (VQIINK) deamidated to
aspartic acid [21]. To investigate the potential role in
fibrillization of this chemical modification we first analyzed
the propensity to fibrillize of 6-mer peptides of sequence
VQIINK and VQIIDK. In the absence of any inducer, the
original sequence (VQIINK) fibrillizes, while no fibrils are
observed for the peptide mimicking the deamidation product
(Fig. 5A). These results are incompatible with the frequent
observation of deamidation in Alzheimer's patients [21]; once
more giving a warning on the relevance of the fibrillization
behavior of such short peptides. Furthermore, quite different
results are obtained when the same chemical modification is
investigated using peptides encompassing the complete repeat
II. Repeat II requires inducers to fibrillize in vitro, and, under
those conditions, no differences are observed between theFig. 6. Assembly of peptide VQIVYK and its variants. (A) Scheme of the localizatio
IIIa in the absence of any added compound. (C) Fibrils assembled from peptide IIIa
phosphorylated. (E) Assembled fibrils of peptide IIIa with its tyrosine replaced by pfibrillization propensity of the original sequence and the
deamidated product (Fig. 5B).
The equivalent sequence in repeat III (i.e., fragment IIIa with
sequence VQIVYK) is also a potential target of chemical
modifications affecting its tyrosine, which could be either
iodated [44] or phosphorylated. Fragment IIIa is particularly
interesting because it has been postulated by other authors as the
“nucleus” for the fibrillization reaction of tau [44]. In the
experiments described in the previous section we find that this
fragment might too small to play such a critical role, but does
seem to be part of the fibrillization hotspot in vitro (see above).
Following the same rationale applied above, we investigated the
effect caused by the chemical modifications on the in vitro
fibrillization of this short peptide. Fig. 6B and C show that
iodation of peptide IIIa does not significantly affect its
propensity to self-assemble into fibrils. Fig. 6D shows that the
phosphorylation of tyrosine 310, on the other hand, abolishes
the formation of peptide IIIa fibrils in our experimentaln of peptide IIIa (VQIVYK) in tau molecule. (B) Fibrils assembled from peptide
with its tyrosine iodated. (D) Absence of fibrils of peptide IIIa with its tyrosine
henylalanine.
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also investigated the consequence of replacing tyrosine 310 by
phenylalanine in peptide IIIa. This mutation increases the
hydrophobicity of the sequence, and is not related to
Alzheimer's disease. Fig. 6E shows that this peptide has a
slightly higher propensity to form fibrils, which are more
regular and longer. From these results it is clear that non-
biological modifications that increase the hydrophobicity of the
sequence also increase formation of fibrils in vitro, while
potentially biological modifications, such as phosphorylation,
can eliminate the formation of fibrils. This result is consistent
with the previous finding of Pawar et al. [45]. The combination
of these observations strongly suggests that the in vitro
fibrillization of peptide IIIa is not specific of PHF formation,Fig. 7. Summary of the assembly characteristics of tau peptides located along tau mol
tau fibrillization hotspot. The propensity to fibrillize in the absence or presence of po
propensity of tau and its variants, indicated in Fig. 3A. NA means not analyzed.but a logical consequence of its short sequence and hydrophobic
character.
4. Conclusions
In this work we have analyzed the specificity of tau
fibrillization reaction in the presence of inducers such as
quinones. Additionally, we have mapped the in vitro fibrilliza-
tion hotspot of tau onto the third repeat of its microtubule
binding domain.
Fig. 7 summarizes present and previous results on our efforts
to map the fibrillization hotspot of tau. Looking at Fig. 7 it is
possible to conclude that tau variants containing the second and
third tubulin binding repeats fibrillize in vitro in the presence ofecule. (A) Summary of the data from this and previous works on the mapping of
lymerization inducers is shown using a semi-quantitative scale. (B) Fibrillization
691I. Santa-María et al. / Biochimica et Biophysica Acta 1762 (2006) 683–692quinones. A tau fragment containing residues 305 to 335
displays a high propensity to fibrillize in vitro, although it
requires the presence of inducers. Furthermore, deleting
sections of this sequence severely hampers the ability of tau
to fibrillize in vitro. Several experiments have also tested the
fibrillization propensity of smaller fragments within this area of
tau. A 6-mer peptide comprising residues 306 to 311
(VQIVYK) is able to fibrillize in the absence of any added
compound. Other groups have described that even a tripeptide
containing residues 309 to 311 (AcVYK) can fibrillize in vitro
without inducers [46]. The equivalent 6-mer from repeat II,
comprising residues 275 to 280 (VQIINK), can also self
assemble in the absence of any added compound. Our results,
however, raise serious concerns regarding whether these short
peptides retain the fibrillization behavior of full-length tau, or
are simply forming a non-specific cross beta sheet conformation
in vitro. These concerns are further substantiated by the analysis
of tau chemical modifications related to Alzheimer's disease.
Some of these chemical modifications alter the fibrillization
behavior of the short peptides in patterns that are incompatible
with their biological role. In the context of the whole protein,
the short fragment 306–311 (peptide IIIa) seems to facilitate tau
fibrillization in vitro, but it is not required for fibrillization in the
presence of quinones, consistently with Gamblin's model for
tau fibrillization [47]. From all these observations we conclude
that the region corresponding to repeat III is the minimal hotspot
for tau fibrillization in vitro.
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